Biotech startup Auristone snags US$4 million in seed funding from Seeds Capital and Elev8

BIOTECH startup Auristone has secured a US$4 million seed funding round led by venture capital firm, Elev8.vc.

Seeds Capital – the investment arm of Enterprise Singapore, along with existing investor Genedant, joined the round of funding.

Aditya Mathur, managing director, Elev8.vc, said: “The human epigenome is the next frontier for unlocking precision healthcare. Auristone stands out in this field, with their ability to profile molecules and predict their medical interactions using epigenomics biomarkers.”

The startup is focused on epigenomics or the science of how genes are expressed. Auristone’s flagship product is a molecular profiling tech, EPI-CALL, which helps predict an individual’s likelihood of response to different treatment options for cancer.

The funding will be used to drive more clinical collaborations and market adoption of EPI-CALL.

Tan Kaixin, general manager, Seeds Capital, said: “Seeds Capital looks forward to supporting Auristone as it scales into new markets such as South Korea, Japan and beyond. We are excited to partner with the team to further the adoption of epigenomics in genomic testing and create better, personalised healthcare.”